UNSPSC 51401557: Adinazolam

This classification denotes a benzodiazepine with the molecular formula C19H18ClN5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KN08449444, chemically known as 8-chloro-1-((dimethylamino)methyl)-6-phenyl-4h-s-triazolo(4,3-a)(1,4)benzodiazepine but generally known as adinazolam, which bears US NIH Compound Identifier 37632. Adinazolam most often comes in forms mesylate and monomethanesulfonate. European Medicines Agency schedules Adinazolam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05271MIG.

UNSPSC 51401557 Adinazolam, a Commodity code, nominally describes a specific benzodiazepine anxiolytic, but recent state and local procurement activity under this code shows no solicitations for adinazolam itself. Instead, issuing bodies are using the code to tag purchases of opioid-antagonist medications (naloxone), pharmaceutical supply chain and direct-to-manufacturer contracting services, and generic multi-source pharmaceuticals and over-the-counter products for public health and human services delivery. The mismatch between the code's nominal scope and actual procurement suggests either a tagging error in the source data or repurposing of the commodity code to cover a broader pharmaceutical-procurement family. State and local health departments, cooperative purchasing alliances, and state health and human services commissions are the primary issuing bodies, with activity spanning county-level community health initiatives and multistate cooperative procurement programs.

Recent opportunities include Seminole County, Florida issuing an IFB (number IFB60459723LAS, due July 26, 2023) for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly delivery to the county community health building; the Texas Health and Human Services Commission issuing an RFI (HHS0017013, posted April 3, 2026) to gather market intelligence on direct-to-manufacturer prescription program capabilities; and the Minnesota Multistate Cooperative Purchasing Alliance issuing an RFP (S1070000015802, due March 26, 2026) to establish contracts for generic pharmaceuticals and OTC products through authorized wholesalers, with awards effective July 1, 2026. Procurement activity appears concentrated in Florida and Texas, with multistate reach through Minnesota's cooperative purchasing vehicle extending to Oregon. The code shows little genuine recent activity aligned to adinazolam procurement specifically.